Current stock page

Financial Data

TARS Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TARSTarsus Pharmaceuticals, Inc.

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 8/10
$80.28+$3.39 (+4.41%)

Latest quote

  • Momentum
    76
  • Value
    75
  • Quality
    50
  • Risk resilience
    59
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$194.57M$173.91M$162.05M$151.67M$118.7M$102.66M$78.34M$66.41M
Gross Profit$180.68M$161.8M$152.66M$140.74M$94.1M$96.42M$73.12M$61.48M
Operating Income-$662.09M-$19.91M-$6.12M-$7.98M-$14.53M-$22.18M-$26.28M-$24.42M
Net Income-$668.33M-$18.55M-$6.97M-$8.37M-$12.59M-$20.34M-$25.12M-$23.11M
EPS-$14.4-$0.43-$0.16-$0.2-$0.3-$0.48-$0.64-$0.6
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$6M$66.77M-$24.65M$19.33M$18.26M-$29.39M-$20.65M-$22.18M
Capital Expenditure-$1.21M-$4.07M-$5.82M-$6.36M-$1.91M-$1M-$590K-$5.07M
Free Cash Flow-$7.22M$62.7M-$30.47M$12.97M$16.35M-$30.39M-$21.24M-$27.25M
Net Cash Provided By Operating Activities-$6M$66.77M-$24.65M$19.33M$18.26M-$29.39M-$20.65M-$22.18M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$505.5M$611.14M$581.14M$562.16M$534.56M$494.99M$500.75M$376.99M
Total Debt$88.67M$88.66M$88.68M$93.64M$82.51M$72.45M$72.37M$72.45M
Cash And Cash Equivalents$136.53M$204.6M$102.19M$183.64M$112.72M$96.65M$175.79M$94.82M
Total Liabilities$401.47M$264.41M$232.18M$218.73M$199.48M$162.38M$158.29M$152.46M
Total Stockholders Equity$104.03M$346.73M$348.95M$343.43M$335.08M$332.61M$342.46M$224.53M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio30.618.187.978.679.095.35.787.09
P/S ratio5.46———————
Debt To Equity0.850.260.250.270.250.220.210.32
Free Cash Flow Yield1.19%2.17%-1.13%-0.75%-2.05%-4.98%-3.68%-5.63%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio30.618.187.978.679.095.35.787.09
P/S ratio5.46———————
Return On Equity-6.75%-13.40%-13.83%-19.34%-24.22%-27.66%-30.64%-51.46%
Debt To Equity0.850.260.250.270.250.220.210.32

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-5.29x
Pb35.82x
Revenue Growth Yoy63.92%
EPS Growth Yoy-4700.00%
Gross Margin93.21%
Operating Margin-102.04%
ROE-245.72%
ROIC-250.05%
Debt To Equity0.85
FCF Yield0.96%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$80.28
Volume732,093
RSI (14)64.82
MACD0.81
MACD signal-0.25
MACD histogram1.06
ADX (14)16.69
SMA (50)$74.85
SMA (200)$67.97
ATR (14)$3.82
Historical volatility (annualized)44.69%
Volume (20-day average)861,584

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score59/100
Beta0.56
Annual volatility45.02%
Max Drawdown-32.00%
Sharpe Ratio0.36
VaR (95%, 1-day)-4.22%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TARS Financial Data FAQ

What is Tarsus Pharmaceuticals, Inc.'s revenue?

Tarsus Pharmaceuticals, Inc.'s revenue is one of the core financial data points for TARS. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Tarsus Pharmaceuticals, Inc.'s revenue growing?

Revenue growth shows whether Tarsus Pharmaceuticals, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TARS's EPS?

TARS's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Tarsus Pharmaceuticals, Inc.'s net income?

Tarsus Pharmaceuticals, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Tarsus Pharmaceuticals, Inc. generate?

Free cash flow shows how much cash Tarsus Pharmaceuticals, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Tarsus Pharmaceuticals, Inc. have?

Cash and debt help frame TARS's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.